Abstract
It has been proposed that diabetes was associated with an increased risk of cancer mortality and morbidity. Complex mechanisms are involved in the association between diabetes and cancer. Metformin has been suggested to reduce the risk of cancer incidence (Hazard ratio 0.63 (95% CI 0.53- 0.75)) or cancer mortality (Hazard ratio 0.43 (95% CI 0.23-0.80)), but insulin or sulfonylurea is suspected to increase the risk of cancer incidence (Hazard ratio 1.36 (95% CI 1.19-1.54)) or cancer mortality (Hazard ratio 1.30 (95% CI 1.10-1.60)). Evidences on these issues are reviewed and summarized in this chapter.
Keywords: Diabetes, anti-diabetic drugs, cancer motality and morbidity.
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Diabetes Reviews
Current Neurovascular Research
Current Respiratory Medicine Reviews
Current Pediatric Reviews
Infectious Disorders - Drug Targets
Current Stem Cell Research & Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current Alzheimer Research
Current Aging Science
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents